(MedPage Today) -- GOTHENBURG, Sweden -- Early treatment with glatiramer (Copaxone) proved superior to later treatment in reducing conversion to definite multiple sclerosis in patients with a clinically isolated syndrome, researchers said here.
Read from Source
|
